Liftstream is an executive search recruitment company in the life sciences sector
Swedish biotech Oxthera raises $10m for Orphan Drug Development
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged biopharmaceutical, clinical development, finance, funding, Gentium, Jazz Pharma, Kidney Failure in enteric hyperoxaluria, KLS Partners, Kurma Partners, Mayo Clinic, Medicon Valley, Oxabact, Oxazyme, Oxthera, primary hyperoxaluria, Remi Droller, sweden
Leave a comment
David Roth appointed Chief Medical Officer of Infinity
Authored by Karl Simpson
Posted in Executive Appointments, Orphan Drugs and Rare Diseases
Tagged Boston Biotech, Chief Medical Officer, chronic myelogenous leukemia, clinical development, CMO, David Roth, haemophilia A, Harvard, He, Infinity Pharmaceuticals, Julian Adams, Massachusetts Institutue of Technology, Medical Affairs, Pfizer, Senior Vice President, Wyeth
Leave a comment
Shire expands rare disease reach with Viropharma Purchase
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged acquisition, Basingstoke, Cinryze, clinical development, EU, Flemming Ornskov, Geneva, immune disorder hereditary angioedema, Lotus Tissue Repair, marketed products, Pipeline, regulatory approval, restructure, SARcode, Shire, Shire HGT, Shire Rare Disease, Switzerland, USA, Viropharma, Zug
Leave a comment
Roche Returns to Antibiotics with Polyphor Deal
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged A*STAR, antibiotics, AstraZeneca, bacterial infection, CDC, Center for Disease Control & Prevention, clinical development, ETC and ETPL, gRED, Head of Infectious Diseases Discovery and Translational, hospital-acquired infection, infection, Infectious Disease, John Reed, macrocycle, partnering, Polyphor, pRED, Pseudomonas aeruginosa, Roche, Singapore, Switzerland, Tom Frieden
Leave a comment
AstraZeneca scouting late stage options
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged aquisitions, AstraZeneca, AZ, clinical development, Crestor, LABA, LAMA, M&A, Novartis, Pascal Soriot, Pearl Therapeutics, PT003
Leave a comment
AstraZeneca still fishing for deals
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged AlphaCore, Amarin, AstraZeneca, blockbuster, clinical development, combination, commercialisation, Crestor, Epanova, europe, fish oil, generic competition, GSK, Horizon Discovery, Lovaza, low risk, M&A, Moderna Therapeutics, Omthera Pharma, partnering deals, Pascal Soriot, Pipeline, purchases, statins, USA, Vascepa, very high triglycerides
Leave a comment
Avastin disappoints in study for treatment of Brain Cancer
Authored by Karl Simpson
Posted in Pharmaceutical business
Tagged Avastin, brain cancer, chemo, clinical development, FDA, Glioblastoma, Houston, MD Anderson Cancer Center, Merck, oncology, PFS, Roche, temador, USA
Leave a comment
Omeros into phase 1 clinical trial in Europe
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged aHUS, Alexion, clinical development, Gregory Demopulos, mannan-binding lectin-associated serine protease-2, MASP-2, Omeros Corporation, Omeros Pharma, OMS721, Phase II, Soliris, thrombotic microangiopathy, uremic syndrome, US Biotech
Leave a comment